Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2525440 | 0.88 | — | — | |
| SCHEMBL18322450 | 0.85 | RIPK1 (0.34) | RIPK1DPP4 | |
| SCHEMBL1810381 | 0.85 | NR1H2 (0.33) | RIPK1DPP4 | |
| SCHEMBL1640341 | 0.84 | RIPK1 (0.31) | RIPK1DPP4 | |
| SCHEMBL482006 | 0.84 | NCF1 (0.36) | RIPK1DPP4 | |
| SCHEMBL619575 | 0.83 | TYMP (0.33) | RIPK1DPP4 | |
| SCHEMBL5345793 | 0.81 | SMYD3 (0.38) | DPP4 | |
| SCHEMBL3504553 | 0.81 | — | — | |
| SCHEMBL7990391 | 0.81 | PREP (0.31) | — | |
| SCHEMBL4752421 | 0.81 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11034680-B2 | Apoptosis inhibitors | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2021-06-15 | — | — | US | disclosed |
| US-20210107871-A1 | BIARYL SULFONAMIDE DERIVATIVE HAVING FILOVIRUS CELL ENTRY INHIBITION ACTIVITY | NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (JP) | 2021-04-15 | — | — | US | disclosed |
| WO-2021057190-A1 | QUINOLINE COMPOUNDS, PREPARATION METHOD THEREFOR AND USE THEREOF | 上海阳帆医药科技有限公司 | 2021-04-01 | — | — | WO | disclosed |
| EP-3484854-B1 | APOPTOSIS INHIBITORS | NAT INSTITUTE OF BIOLOGICAL SCIENCES BEIJING (CN) | 2021-01-20 | — | — | EP | disclosed |
| EP-3611161-A1 | BIARYL SULFONAMIDE DERIVATIVE HAVING FILOVIRUS CELL ENTRY INHIBITION ACTIVITY | National University Corporation Hokkaido University (JP) | 2020-02-19 | — | — | EP | disclosed |
| US-20190152976-A1 | TRIAZOLOPYRIDINES AND TRIAZOLOPYRAZINES AS LSD1 INHIBITORS | INCYTE CORPORATION | 2019-05-23 | — | — | US | disclosed |
| US-20190152960-A1 | Apoptosis Inhibitors | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2019-05-23 | — | — | US | disclosed |
| US-10138249-B2 | Triazolopyridines and triazolopyrazines as LSD1 inhibitors | INCYTE CORPORATION (US) | 2018-11-27 | — | — | US | disclosed |
| US-20170362245-A1 | TRIAZOLOPYRIDINES AND TRIAZOLOPYRAZINES AS LSD1 INHIBITORS | INCYTE CORPORATION | 2017-12-21 | — | — | US | disclosed |
| US-9758523-B2 | Triazolopyridines and triazolopyrazines as LSD1 inhibitors | INCYTE CORPORATION (US) | 2017-09-12 | — | — | US | disclosed |
| US-20160009721-A1 | TRIAZOLOPYRIDINES AND TRIAZOLOPYRAZINES AS LSD1 INHIBITORS | INCYTE CORPORATION | 2016-01-14 | — | — | US | disclosed |
| WO-2016007727-A1 | TRIAZOLOPYRIDINES AND TRIAZOLOPYRAZINES AS LSD1 INHIBITORS | INCYTE CORPORATION (US) | 2016-01-14 | — | — | WO | disclosed |
| US-8263623-B2 | Triazol derivatives useful for the treatment of diseases | PFIZER INC. (US) | 2012-09-11 | — | — | US | disclosed |
| US-20100010040-A1 | Triazol Derivatives Useful For The Treatment of Diseases | PFIZER INC | 2010-01-14 | — | — | US | disclosed |
| US-20080275043-A1 | Cycloalkyl Lactam Derivatives as Inhibitors of 11-Beta-Hydroxysteroid Dehydrogenase 1 | ELI LILLY AND COMPANY | 2008-11-06 | — | — | US | disclosed |
| US-7253286-B2 | Urea derivatives containing aromatic or heteroaromatic rings, useful as prophylactic or therapeutic agent for a disease for which angiogenesis inhibition is effective | EISAI CO., LTD (JP) | 2007-08-07 | — | — | US | disclosed |
| US-20040053908-A1 | Urea derivatives containing aromatic or heteroaromatic rings, useful as prophylactic or therapeutic agent for a disease for which angiogenesis inhibition is effective | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2004-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100010040-A1 | Triazol Derivatives Useful For The Treatment of Diseases | TSLP, IL5, EPX | RIPK1 2854/4885DPP4 930/4885 |
| US-20190152960-A1 | Apoptosis Inhibitors | BAX, SDHA, SDHB | RIPK1 991/4885DPP4 2429/4885 |
| US-20040053908-A1 | Urea derivatives containing aromatic or heteroaromatic rings, useful as prophylactic or therapeutic agent for a disease for which angiogenesis inhibition is effective | VEGFA, UACA, UTS2R | RIPK1 4711/4885DPP4 3108/4885 |
| US-20080275043-A1 | Cycloalkyl Lactam Derivatives as Inhibitors of 11-Beta-Hydroxysteroid Dehydrogenase 1 | HSD11B1, HSDL2, HSD17B1 | RIPK1 3787/4885DPP4 508/4885 |
| US-20160009721-A1 | TRIAZOLOPYRIDINES AND TRIAZOLOPYRAZINES AS LSD1 INHIBITORS | KDM1B, KDM5A, KDM1A | RIPK1 1743/4885DPP4 694/4885 |
| US-10138249-B2 | Triazolopyridines and triazolopyrazines as LSD1 inhibitors | KDM1B, KDM5A, KDM1A | RIPK1 1743/4885DPP4 694/4885 |
| US-20170362245-A1 | TRIAZOLOPYRIDINES AND TRIAZOLOPYRAZINES AS LSD1 INHIBITORS | KDM1B, KDM5A, KDM1A | RIPK1 1743/4885DPP4 694/4885 |
| US-20190152976-A1 | TRIAZOLOPYRIDINES AND TRIAZOLOPYRAZINES AS LSD1 INHIBITORS | KDM1B, KDM5A, KDM1A | RIPK1 1743/4885DPP4 694/4885 |
| US-11034680-B2 | Apoptosis inhibitors | BAX, SDHA, SDHB | RIPK1 991/4885DPP4 2429/4885 |
| US-20210107871-A1 | BIARYL SULFONAMIDE DERIVATIVE HAVING FILOVIRUS CELL ENTRY INHIBITION ACTIVITY | FLNA, FLNB, BRI3BP | RIPK1 2384/4885DPP4 441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.